Acute Migraine Treatment Market Projected to Reach USD 8.6 Billion by 2032, Growing at a 4.9% CAGR

Posted on 2024-10-08 by Future Market Insights in Healthcare, Pharmaceuticals // 0 Comments

Acute Migraine Treatment Market

The global acute migraine treatment market is on a promising growth trajectory, with projections indicating a market valuation of approximately USD 2.4 billion in 2022. The market is expected to exhibit a compound annual growth rate (CAGR) of 4.9% from 2022 to 2032, ultimately reaching USD 8.6 billion by the end of the forecast period.

This anticipated growth is largely driven by the rising prevalence of migraines, which can be attributed to the rapid adoption of unhealthy lifestyles. As the incidence of migraine continues to increase, so too does the demand for effective acute treatment options, creating a substantial opportunity for growth in the market.

Healthcare providers and pharmaceutical companies are focusing on developing innovative solutions to address the needs of migraine sufferers, emphasizing the importance of effective treatment strategies. The commitment to improving patient outcomes is expected to propel the market forward, ultimately enhancing the quality of life for individuals affected by this debilitating condition.

Global Acute Migraine Treatment Industry Dynamics
The rising number of population and the growing prevalence of migraine is expected to drive the market of acute migraine treatment in the forecast period. An increasing female population as the disease is more prevalent in females further accelerates the growth of the acute migraine treatment industry. Growing healthcare expenditure, rising adoption of unhealthy lifestyles, and growing awareness regarding acute migraine and its treatment further spur the market of acute migraine treatment globally.

However, stringent regulation for drug approval, high cost of treatment, adverse side effects, lack of proper diagnosis, and growing preference for alternative time therapies are some of the facthinderingnder the growth of the acute migraine treatment industry

Acute Migraine Treatment Market Overview
The emergence of new drugs and therapies for acute migraine treatment is expected to account for the significant growth of acute migraine treatment in the forecast The development of new drugs such as CGRP antagoprovides provides huge potential for the Global Acute Migraine Treatment Industry to grow. The development of new drugs by key pharmaceutical players such as Amgen, Novartis, Eli Lily, and Company and increasing research and development funding will create a huge opportunity for the market to grow shortly. For instance, in 2017, Eli Lilly and Company’s drug for acute migraine treatment succeeded in a key late-stage study, setting the stage for regulatory approval in the US

Acute Migraine Treatment: Region-wise Out

North America is expected to contribute to a major share of the global acute migraine treatment, duthe e to the growing prevalence of acute migraine along with the increasing funding for the development of drugs with the presence of major pharmaceutical industries. According to the Migraine Research Foundation, 39 million of the US population suffer from migraine, and 1 billion population worldwide. 18% of women, 6% of men, and 10% of children suffer from migraines. In 2015, the medical cost of treating migraine was more than $5.4 billion, although migraine patients spent over $41 billion on treating the entire range of migraine.

Europe accounts for the second largest market share and registers significant growth in the global acute-migraine treatment market, due to the increasing demand for effective treatment for acute migraine and the adoption of new therapies along with favorable reimbursement scenarios. Asia Pacific market is primarily driven by factors such as increasing expenditure on healthcare systems, improvement in the healthcare infrastructure, and growing awareness of disease. China is expected to register significant growth in the acute-migraine treatment market, due to the growing population, low cost of drugs and treatment, and availability of drugs for acute migraine treatment. Due to a lack of developed healthcare facilities, Latin America and the Middle East & Africa are projected to show sluggish growth in the Global Acute Migraine Treatment Industry.

Acute Migraine Treatment Market: Key Players
Some of the key players present in the Global Acute Migraine Treatment Industry are Amgen, Pfizer Inc., Hoffmann-La Roche Ltd, Eli Lily and Company, Novartis AG, Johnson and Johnson, Merck & Co., AstraZeneca and Teva Pharmaceutical among others.

Acute Migraine Treatment Market: Segmentation
The Global Acute Migraine Treatment Industry is segmented based on drug type, distribution channel, and geography.

Segmentation by Drug Type

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Triptans
Dihydroergotamine
Nonspecific Migraine Medications
Analgesics

Segmentation by Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Matched content

Editor’s pick